查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球诺罗病毒诊断市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按产品、按技术、按等级、按应用、按最终用户、按地区
市场调查报告书
商品编码
1394141

全球诺罗病毒诊断市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按产品、按技术、按等级、按应用、按最终用户、按地区

Norovirus Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 245 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球诺罗病毒诊断市场规模预计在 2024 年至 2031 年间将以 8.7% 的复合年增长率 (CAGR) 快速增长，到 2031 年达到 1.3 亿美元。 2024年市场规模为7,000万美元，反映出当前的上升趋势。

这一显着增长的主要驱动力之一是诺罗病毒疾病发病率的上升。 该领域的主要参与者和製造商正在采用先进的技术来对抗这种高度传染性的胃肠道病毒。 因此，医疗设备製造商正在增加研发 (R&D) 投资，以开发更灵敏、更有效率的先进诊断工具。 此类技术创新努力预计将在不久的将来刺激诺罗病毒诊断市场的扩张。

诊断实验室的激增也促进了市场成长，这对製造商的销售和利润产生了积极影响。 随着此类诊断实验室的不断出现，诺罗病毒诊断市场可能会大大受益。

然而，儘管成长前景广阔，但也存在影响诺罗病毒诊断市场的某些障碍。 低收入国家诺罗病毒感染流行以及对诺罗病毒感染前症状缺乏认识等因素阻碍了市场扩张。

诺罗病毒的诊断不足是影响患者健康的另一个问题，由于与该疾病相关的耻辱或对其症状缺乏了解，个人可能不会寻求医疗救助。 诺罗病毒感染的症状，如痉挛、噁心、呕吐、腹泻和低烧，容易与其他疾病混淆，导致误诊和忽视。 应对这些挑战需要努力提高公众意识并教育公众有关诺罗病毒及其诊断方法的知识。

由于诺罗病毒感染率较高，美国在诺罗病毒诊断市场中占有很大份额。 领先公司的存在和不断增加的研发投资正在促进该市场的成长。 此外，旨在加强医疗保健系统和监管能力的政府措施预计将进一步推动市场扩张。

本报告调查了全球诺罗病毒诊断市场，并概述了市场概况、按产品、最终用户、地区划分的趋势以及进入市场的公司的竞争趋势。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第 3 章2018-2031 年全球诺罗病毒诊断市场前景

  • 2018-2031 年全球诺罗病毒诊断市场前景（按产品和价值划分）（百万美元）
  • 全球诺罗病毒诊断市场展望，按最终用户划分，价值（百万美元），2018-2031 年
  • 2018-2031 年全球诺罗病毒诊断市场前景（按地区、价值（百万美元））

第 4 章北美诺罗病毒诊断市场前景，2018-2031

第 5 章欧洲诺罗病毒诊断市场前景，2018-2031

第 6 章亚太地区诺罗病毒诊断市场展望，2018-2031 年

第 7 章拉丁美洲诺罗病毒诊断市场展望，2018-2031 年

第 8 章中东与非洲诺罗病毒诊断市场前景，2018-2031

第九章竞争态势

  • 製造商和最终用户的热图
  • 2023 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • Abbott Laboratories
    • R-Biopharm AG
    • ELITechGroup AG
    • Danaher Corporation (Cepheid)
    • Meridian Bioscience Inc.
    • Eiken Chemical Co.
    • Altona Diagnostics GmbH
    • Elisabeth Pharmacon, Spol. S Ro
    • CerTest Biotec S.L
    • Altona Diagnostics GmbH

第 10 章附录

简介目录

The global Norovirus Diagnostics Market is set to witness substantial growth, with the market projected to surge at a Compound Annual Growth Rate (CAGR) of 8.7% between 2024 and 2031, reaching an estimated valuation of US$ 130.0 Mn by the end of the forecast period. In 2024, the market stood at a value of US$ 70 Mn, reflecting its current upward trajectory.

Rising Incidence of Norovirus Disease

One of the key driving factors behind this remarkable growth is the escalating incidence of norovirus disease. Leading participants and manufacturers in the field are adopting sophisticated techniques to combat this highly contagious stomach and intestinal virus. As a result, medical device companies have increased their Research and Development (R&D) investments to develop advanced diagnostic tools that are more sensitive and efficient. This commitment to innovation is expected to fuel the expansion of the Norovirus Diagnostics Market in the near future.

The proliferation of diagnostics laboratories is also contributing to the market's growth, bringing about favorable effects on sales and revenue for manufacturers. As these diagnostics labs continue to emerge, the market for norovirus diagnostics is set to benefit significantly.

Lack of Awareness about Norovirus

However, despite the promising growth prospects, there are certain impediments affecting the Norovirus Diagnostics Market. Factors such as the prevalence of norovirus infection in low-income nations and the lack of awareness about the symptoms preceding norovirus infection have hindered the market's expansion.

The underdiagnosis of norovirus is another issue impacting patient health, as individuals may not seek medical attention due to the stigma associated with the disease or a lack of understanding about its symptoms. The symptoms of norovirus infection, including cramps, nausea, vomiting, diarrhea, and low-grade fever, can be easily confused with other illnesses, leading to misdiagnosis or neglect. To address these challenges, efforts are needed to raise awareness and educate the public about norovirus and its diagnostic options.

Booming U.S. Market

The United States holds a significant share of the Norovirus Diagnostics Market due to the high prevalence of norovirus infections in the country. The presence of major companies and increased R&D investments have contributed to the growth of this market. Additionally, government initiatives aimed at strengthening healthcare systems and regulatory capacities are expected to further propel market expansion.

Lucrative Prospects in Germany's Medical Wellness Market

In Germany, the medical wellness market is thriving, primarily driven by the country's strong emphasis on fitness and well-being. Major players in the industry are collaborating to develop new products, enhancing the market's growth potential.

China Emerges as a Prominent Market for Medical Wellness

China is becoming a prominent market for medical wellness, with manufacturers focusing on expanding their global presence, expertise, and technological capabilities. This strategic approach is making norovirus diagnostics products more widely accessible in the Chinese market.

Competitive Landscape Analysis

The introduction and approval of innovative products are central elements of these manufacturers' strategies to enhance their market presence.

Key Companies Profiled:

  • Abbott
  • R-Biopharm AG
  • ELITechGroup AG
  • Danaher Corporation (Cepheid)
  • Meridian Bioscience Inc.
  • Eiken Chemical Co.
  • Altona Diagnostics GmbH
  • CerTest Biotec S.L
  • Elisabeth Pharmacon, Spol. S Ro
  • Qiagen
  • Altona Diagnostics GmbH
  • Eiken Chemical Co

With the global norovirus diagnostic market on a steady growth trajectory, these developments and trends highlight the promising future of diagnostics for norovirus infection, offering hope for more accurate and timely detection and treatment.

Key Segments Covered in Norovirus Diagnostics Industry Research

By Product

  • Rapid Test Kits
  • PCR Kits
  • ELISA based kits

By End-User

  • Hospitals
  • Diagnostics Labs
  • Clinics

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Norovirus Diagnostics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 3.1. Global Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Rapid Test Kits
      • 3.1.1.2. PCR Kits
      • 3.1.1.3. ELISA based kits
  • 3.2. Global Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospitals
      • 3.2.1.2. Diagnostics Labs
      • 3.2.1.3. Clinics
  • 3.3. Global Norovirus Diagnostics Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 4.1. North America Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Rapid Test Kits
      • 4.1.1.2. PCR Kits
      • 4.1.1.3. ELISA based kits
  • 4.2. North America Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospitals
      • 4.2.1.2. Diagnostics Labs
      • 4.2.1.3. Clinics
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 5.1. Europe Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Rapid Test Kits
      • 5.1.1.2. PCR Kits
      • 5.1.1.3. ELISA based kits
  • 5.2. Europe Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospitals
      • 5.2.1.2. Diagnostics Labs
      • 5.2.1.3. Clinics
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Rapid Test Kits
      • 6.1.1.2. PCR Kits
      • 6.1.1.3. ELISA based kits
  • 6.2. Asia Pacific Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospitals
      • 6.2.1.2. Diagnostics Labs
      • 6.2.1.3. Clinics
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 7.1. Latin America Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Rapid Test Kits
      • 7.1.1.2. PCR Kits
      • 7.1.1.3. ELISA based kits
  • 7.2. Latin America Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Hospitals
      • 7.2.1.2. Diagnostics Labs
      • 7.2.1.3. Clinics
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Rapid Test Kits
      • 8.1.1.2. PCR Kits
      • 8.1.1.3. ELISA based kits
  • 8.2. Middle East & Africa Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospitals
      • 8.2.1.2. Diagnostics Labs
      • 8.2.1.3. Clinics
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by End User Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Abbott Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. R-Biopharm AG
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. ELITechGroup AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Danaher Corporation (Cepheid)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Meridian Bioscience Inc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Eiken Chemical Co.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Altona Diagnostics GmbH
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Elisabeth Pharmacon, Spol. S Ro
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. CerTest Biotec S.L
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Altona Diagnostics GmbH
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations